ADMA Biologics Reports FDA Compliance Status for its
Manufacturing Facility has Improved
Our proprietary microneutralization assay allows us to identify and isolate donor plasma with high-titer RSV antibodies and to standardize RI-002's antibody profile.
Leveraging our immunotechnology platform, we intend to develop additional plasma-derived products through direct R&D and potential licensing opportunities. These follow-on products may include infectious disease-specific IVIG product candidates targeting immunocompromised patients with PIDD as well as transplant patients. Future product candidates could focus on the management of chronic viral and bacterial infections.